BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16279664)

  • 1. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis].
    Ikeda K; Fukagawa M
    Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664
    [No Abstract]   [Full Text] [Related]  

  • 2. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S; Fukawa T; Kamiya S
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
    Takeuchi Y
    Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New bone density conservation agents for osteoporosis under research and development: ED-71].
    Hagino H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
    [No Abstract]   [Full Text] [Related]  

  • 6. D-hormones for prevention of bone loss after organ transplant.
    Sambrook PN
    J Rheumatol Suppl; 2005 Sep; 76():41-3. PubMed ID: 16142850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
    Shiraki M
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination and sequential therapy with PTH and bisphosphonates.
    Bauer DC
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):407. PubMed ID: 15758282
    [No Abstract]   [Full Text] [Related]  

  • 9. [PTH injection for the treatment of osteoporosis].
    Sugimoto T
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():544-51. PubMed ID: 11979953
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of PTH on bone structural properties].
    Ito M
    Clin Calcium; 2012 Mar; 22(3):335-41. PubMed ID: 22370300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parathyroid and bone. The mechanism of anabolic function of parathyroid hormone on bone].
    Ogata N; Kawaguchi H
    Clin Calcium; 2007 Dec; 17(12):1843-9. PubMed ID: 18057659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy for osteoporosis].
    Kishimoto H
    Nihon Rinsho; 2009 May; 67(5):975-9. PubMed ID: 19432119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic agents for disorders of bone and calcium metabolism--Parathyroid hormone in weekly subcutaneous injection].
    Uzawa T
    Clin Calcium; 2007 Jan; 17(1):56-62. PubMed ID: 17211094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bone remodeling: new therapeutic approaches].
    Ferrari S
    Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Human parathyroid hormone (1-34) as a new therapeutic agent for osteoporosis].
    Isogai Y
    Clin Calcium; 2005 Jan; 15(1):18-24. PubMed ID: 15632468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
    Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488
    [No Abstract]   [Full Text] [Related]  

  • 17. Parathyroid hormone: a double-edged sword for bone metabolism.
    Qin L; Raggatt LJ; Partridge NC
    Trends Endocrinol Metab; 2004 Mar; 15(2):60-5. PubMed ID: 15036251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
    Ziegler R
    Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
    [No Abstract]   [Full Text] [Related]  

  • 19. [Morphological analysis of bone dynamics and metabolic bone disease. Effects of parathyroid hormone on bone tissue].
    Miyakoshi N
    Clin Calcium; 2011 Apr; 21(4):575-81. PubMed ID: 21447925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
    Howard E; Tagliarino-Jones H
    Am Fam Physician; 2010 Feb; 81(4):439. PubMed ID: 20148496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.